Nasus Pharma (NSRX) founder discloses share and warrant stakes

Rhea-AI Filing Summary

Nasus Pharma Ltd founder and Executive Chairman Udi Gilboa has filed an initial Form 3 detailing his ownership in the company. He reports direct ownership of 1,919,281 Ordinary Shares and indirect ownership of 5,195 Ordinary Shares held by Formulex Pharma Innovations Ltd., where he is a beneficial owner. He also holds Warrants that are immediately exercisable to purchase up to 17,970 Ordinary Shares at an exercise price of $6.53 per share. These Warrants were issued on February 13, 2026 and will expire on the earlier of two years from issuance or 30 trading days after Nasus announces top-line results of its NS002 Pivotal Study.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Gilboa Udi

Role Insider

Type	Security	Shares	Price	Value
holding	Warrants	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Warrants — 17,970 shares (Direct); Ordinary Shares — 1,919,281 shares (Direct); Ordinary Shares — 5,195 shares (Indirect, By Formulex Pharma Innovations Ltd.)

Footnotes (1)

1. Represents ordinary shares of the Issuer, no par value ("Ordinary Shares") directly held by Formulex Pharma Innovations Ltd. ("Formulex"). Mr. Udi Gilboa, as a beneficial owner of Formulex, may be deemed to beneficially own the Ordinary Shares owned directly by Formulex. The warrants to purchase up to 17,970 Ordinary Shares (the "Warrants") were issued on February 13, 2026. The Warrants have an exercise price of $6.53 per share, were immediately exercisable, and will expire upon the earlier of two years from the date of issuance and 30 trading days following the Issuer's announcement of the top-line results of the Issuer's NS002 Pivotal Study.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gilboa Udi

(Last) (First) (Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO 6100201

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Founder & Executive Chairman

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	1,919,281	D
Ordinary Shares	5,195	I	By Formulex Pharma Innovations Ltd.(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	02/13/2026	(2)	Ordinary Shares	17,970	$6.53	D

Explanation of Responses:

1. Represents ordinary shares of the Issuer, no par value ("Ordinary Shares") directly held by Formulex Pharma Innovations Ltd. ("Formulex"). Mr. Udi Gilboa, as a beneficial owner of Formulex, may be deemed to beneficially own the Ordinary Shares owned directly by Formulex.

2. The warrants to purchase up to 17,970 Ordinary Shares (the "Warrants") were issued on February 13, 2026. The Warrants have an exercise price of $6.53 per share, were immediately exercisable, and will expire upon the earlier of two years from the date of issuance and 30 trading days following the Issuer's announcement of the top-line results of the Issuer's NS002 Pivotal Study.

	/s/ Udi Gilboa	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What ownership does Udi Gilboa report in Nasus Pharma (NSRX) on this Form 3?

Udi Gilboa reports direct ownership of 1,919,281 Ordinary Shares and indirect ownership of 5,195 Ordinary Shares through Formulex Pharma Innovations Ltd. He also reports Warrants to purchase up to 17,970 additional Ordinary Shares at an exercise price of $6.53 per share.

What warrants related to Nasus Pharma (NSRX) does Udi Gilboa hold?

Gilboa holds Warrants to purchase up to 17,970 Nasus Pharma Ordinary Shares at $6.53 per share. The Warrants were issued on February 13, 2026, are immediately exercisable, and provide potential additional equity exposure beyond his existing Ordinary Share holdings.

When do Udi Gilboa’s Nasus Pharma (NSRX) warrants expire?

The Warrants will expire on the earlier of two years from their February 13, 2026 issuance date or 30 trading days after Nasus Pharma announces top-line results of its NS002 Pivotal Study. This links their lifespan directly to a key clinical milestone.

How are indirect Nasus Pharma (NSRX) holdings reported for Udi Gilboa?

The Form 3 states 5,195 Ordinary Shares are held indirectly through Formulex Pharma Innovations Ltd. As a beneficial owner of Formulex, Udi Gilboa may be deemed to beneficially own those shares, in addition to his directly held Ordinary Shares in Nasus Pharma.

Does this Nasus Pharma (NSRX) Form 3 show any recent insider buying or selling?

No specific purchases or sales are shown. The Form 3 functions as an initial statement of beneficial ownership, listing Gilboa’s existing Ordinary Shares and Warrants positions, rather than reporting new buy or sell transactions in Nasus Pharma securities.